N/A N=186 Thoracic Ultrasonography for Pulmonary Edema in Patients With Pre-Eclampsia
Pre-eclampsia
Primary: Detection of Fluid in the Lungs — 2; 3 Participants — p=.162
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=33 Hemodynamics and Extravascular Lung Water in Acute Lung Injury
Acute Lung Injury
Primary: The Primary Efficacy Variable Will be the Total Reduction in Measured Lung Water
N/A N=21 Lung Ultrasound in PD Patients
Peritoneal Dialysis · Hypervolemia · VEGF Overexpression
Primary: Association Between Number of Kerley B Lines by Ultrasound and Serum VEGF-C Level (pg/ml) by Enzyme-linked Immunosorbent Assay — 0.29; 0.25; 0.33 ng/ml — p=0.039
Phase 2 N=130 B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial
Heart Failure · Heart Failure Acute · Acute Cardiac Pulmonary Edema
Primary: Number of Participants With B-lines ≤ 15 at the Conclusion of ED AHF Management — 7; 10 Participants
Phase 3 N=45 Furosemide and Albumin for Diuresis of Edema: A Pilot Randomized Controlled Trial
Edema · Hypoproteinemia
Primary: Ventilator-free Days — 4; 13 days
Phase 4 N=129 Non Invasive Mechanical Ventilation in Acute Cardiogenic Pulmonary Edema
Acute Cardiogenic Pulmonary Edema
Primary: Number of Patients Who Were Intubated — 5; 4; 10 participants
Phase 2 N=122 A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)
Heart Failure, Congestive · Edema
Primary: Body Weight — -0.53; -1.62; -1.35; -1.85 Kg — p=0.0074
Phase 3 N=20 A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)
Cardiac Edema
Primary: Body Weight — -1.68; -2.14 Kg
Phase 2 N=157 A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])
Cardiac Edema (CHF)
Primary: Change in Body Weight From Baseline to Last Assessment Time Point (the Day After IMP Administration) by Day 8 — -1.96; -1.74; -1.4; -1.84 kg
N/A N=14 Effects of Exercise Training on Fluid Instability in Heart Failure Patients
Heart Failure
Primary: Bioelectrical Impedance Change — 47.52; 47.1; 41.27; 46.8 Percentage of Extra Cellular Fluid
Phase 3 N=110 A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)
Edema, Cardiac
Primary: Body Weight (Amount of Change) — -0.45; -1.54 Kg — p=<0.0001
N/A N=21 Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea.
Sleep Apnea, Obstructive · Hypertension, Pulmonary · Heart Failure
Primary: Pulmonary Artery Systolic Pressure. — 58.6; 62.7; 42.8; 57.5 mmHg
N/A N=746 Pulmonary Embolism as a Cause of COPD Exacerbations
Pulmonary Embolism · Chronic Obstructive Pulmonary Disease
Primary: All-cause Mortality, Symptomatic Venous Thromboembolism Recurrence, or Need for Readmission. — 110; 107 Participants
Phase 2 N=104 A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema
Cirrhosis
Primary: Body Weight (Amount of Change) — -0.68; -2.31; -1.88; -1.67 Kg — p=0.3167
N/A N=106 FlowTriever Pulmonary Embolectomy Clinical Study
Pulmonary Embolism · Acute Pulmonary Embolism · Submassive Pulmonary Embolism
Primary: Change in RV/LV Ratio — 0.38 RV/LV ratio — p=< 0.0001
Phase 1 N=36 A Method Validation Study for Evaluation of Novel Treatments Limiting Pulmonary Oedema in Cardiac Failure
Heart Failure, Congestive
Primary: Interstitial Volume (ve) in Heart Failure Participants and Healthy Volunteers at Baseline — 0.4946; 0.3346; 0.5078; 0.3253 Liter — p=0.0029
N/A N=25 Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters
Phase 4 N=581 Chemoprophylaxis Plus Early Ambulation
Pulmonary Embolism · Thoracic Surgery
Primary: Incidence of Postoperative Pulmonary Embolism (PE) in Surgical Thoracic Patients Under Currently Used PE Prevention Strategies. — 3 Participants
N/A N=1,480 An International Pulmonary Embolism Registry Using EKOS
Pulmonary Embolism and Thrombosis
Primary: Change in RV/LV Ratio on Echocardiogram (Matched Pairs as Available) — -22.6; -22.6 Percent change
Phase 2 N=78 Nitric Oxide to Treat Pulmonary Embolism
Pulmonary Embolism
Primary: Number of Participants With Normal Right Ventricular (RV) Function and Viability — 9; 5 Participants
N/A N=139 Non-Contrast 4DCT to Detect Pulmonary Thromboembolic Events
Pulmonary Thromboembolisms · Pulmonary Embolism
Primary: Correlation of 4DCT Identified Perfusion With SPECT/CT Identified Perfusion — 0.45 Spearman correlation
Phase 4 N=57 Loop Diuretics Administration and Acute Heart Failure
Acute Heart Failure
Primary: Evaluation of Mean Urine Output Volume During the Infusion Period — 2505; 2140 mL — p=0.04
Phase 3 N=52 A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)
Cardiac Edema
Primary: Body Weight — -2.05; -1.31; -2.9 Kg
N/A N=26 COMMENCE Pulmonary: Clinical Evaluation of Edwards Pericardial Aortic Bioprosthesis (Model 11000A) for Pulmonary Valve Replacement
Pulmonary Valve Insufficiency · Pulmonary Valve Degeneration · Congenital Pulmonary Valve Abnormality
Primary: Percentage of Subject's With Freedom From Device or Procedure Related Death and/or Reoperation at 1-year Post-implant. — 100.0 percentage of subjects
N/A N=198 Chest Tube Drainage of Transudative Pleural Effusions Hastens Liberation From Mechanical Ventilation
Liberation From Mechanical Ventilation
Primary: Total Days of Mechanical Ventilatory Support — 6.51; 4.02 days
Phase 3 N=350 Breath Analysis Technique to Diagnose Pulmonary Embolism
Pulmonary Embolism
Primary: Phase I: Percentage Change in the Postoperative End Tidal CO2/O2 Ratio and D-dimer Concentration Relative to the Preoperative Measurement — 0; 136 percent change
N/A N=114 Non-invasive Ventilation Versus Continuous Positive Airway Pressure in Cardiogenic Pulmonary Edema
Cardiogenic Pulmonary Oedema
Primary: Need for an Endotracheal Intubation Within Seven Days After Onset of Cardiopulmonary Edema at the Intensive Care Unit — 5; 5 Participants — p=1.000
N/A N=115 FlowTriever for Acute Massive Pulmonary Embolism (FLAME)
PE - Pulmonary Embolism · PE - Pulmonary Thromboembolism
Primary: Composite Incidence of All-cause Mortality, Clinical Deterioration, Bailout, and Major Bleeding — 9; 39 Participants
Phase 2 N=18 Sildenafil for Swimming-Induced Pulmonary Edema (SIPE) Prevention
Edema, Pulmonary · Immersion · Diving
Primary: Number of Participants With Pulmonary Edema — 7; 9 Participants — p=0.317
Phase 2 N=29 Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis
Alveolitis, Fibrosing · Fibrosis, Pulmonary · Hypertension, Pulmonary
Primary: Change in 6-minute Walk Test — -26; -7 meters